Literature DB >> 19745786

A pharmacogene database enhanced by the 1000 Genomes Project.

Eric R Gamazon1, Wei Zhang, R Stephanie Huang, M Eileen Dolan, Nancy J Cox.   

Abstract

Human genetic variation is likely to be responsible for a substantial fraction of the variability in complex traits including drug response. Single nucleotide polymorphisms have been implicated in drug response using genome-wide association studies as well as candidate-gene approaches. A more comprehensive catalogue of human genetic variation should complement the current large-scale genotypic dataset from the International HapMap Project, which focuses on common genetic variants. The 1000 Genomes Project is an international research effort that aims to provide the most comprehensive map of human genetic variation using next-generation sequencing platforms. Owing to the lack of convenient tools, however, it is a challenge for the pharmacogenetic research community to take advantage of these data. Here, we present a new database of some pharmacogenes of particular interest to pharmacogenetic researchers. Our database provides a convenient portal for immediate utilization of the newly released 1000 Genomes Project data in pharmacogenetic studies.

Entities:  

Mesh:

Year:  2009        PMID: 19745786      PMCID: PMC2935084          DOI: 10.1097/FPC.0b013e3283317bac

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  14 in total

Review 1.  Current and future potential roles of the platinum drugs in the treatment of ovarian cancer.

Authors:  M J Piccart; H Lamb; J B Vermorken
Journal:  Ann Oncol       Date:  2001-09       Impact factor: 32.976

2.  Detection of large-scale variation in the human genome.

Authors:  A John Iafrate; Lars Feuk; Miguel N Rivera; Marc L Listewnik; Patricia K Donahoe; Ying Qi; Stephen W Scherer; Charles Lee
Journal:  Nat Genet       Date:  2004-08-01       Impact factor: 38.330

3.  A haplotype map of the human genome.

Authors: 
Journal:  Nature       Date:  2005-10-27       Impact factor: 49.962

4.  Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity.

Authors:  Wei Zhang; R Stephanie Huang; M Eileen Dolan
Journal:  Trends Cancer Res       Date:  2008

5.  Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.

Authors:  Josefa Salgado; Natalia Zabalegui; Carmen Gil; Ignacio Monreal; Javier Rodríguez; Jesús García-Foncillas
Journal:  Oncol Rep       Date:  2007-02       Impact factor: 3.906

Review 6.  The impact of next-generation sequencing technology on genetics.

Authors:  Elaine R Mardis
Journal:  Trends Genet       Date:  2008-02-11       Impact factor: 11.639

7.  1000 Genomes Project promises closer look at variation in human genome.

Authors:  Bridget M Kuehn
Journal:  JAMA       Date:  2008-12-17       Impact factor: 56.272

8.  Single-molecule DNA sequencing of a viral genome.

Authors:  Timothy D Harris; Phillip R Buzby; Hazen Babcock; Eric Beer; Jayson Bowers; Ido Braslavsky; Marie Causey; Jennifer Colonell; James Dimeo; J William Efcavitch; Eldar Giladi; Jaime Gill; John Healy; Mirna Jarosz; Dan Lapen; Keith Moulton; Stephen R Quake; Kathleen Steinmann; Edward Thayer; Anastasia Tyurina; Rebecca Ward; Howard Weiss; Zheng Xie
Journal:  Science       Date:  2008-04-04       Impact factor: 47.728

9.  Beyond the HapMap Genotypic Data: Prospects of Deep Resequencing Projects.

Authors:  Wei Zhang; M Eileen Dolan
Journal:  Curr Bioinform       Date:  2008-09-01       Impact factor: 3.543

10.  The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics.

Authors:  Wei Zhang; Mark J Ratain; M Eileen Dolan
Journal:  Bioinform Biol Insights       Date:  2008-02-01
View more
  6 in total

Review 1.  Pharmacogenomic discovery using cell-based models.

Authors:  Marleen Welsh; Lara Mangravite; Marisa Wong Medina; Kelan Tantisira; Wei Zhang; R Stephanie Huang; Howard McLeod; M Eileen Dolan
Journal:  Pharmacol Rev       Date:  2009-12       Impact factor: 25.468

2.  The limits of genome-wide methods for pharmacogenomic testing.

Authors:  Eric R Gamazon; Andrew D Skol; Minoli A Perera
Journal:  Pharmacogenet Genomics       Date:  2012-04       Impact factor: 2.089

3.  SCAN: a systems biology approach to pharmacogenomic discovery.

Authors:  Eric R Gamazon; R Stephanie Huang; Nancy J Cox
Journal:  Methods Mol Biol       Date:  2013

4.  PharmGKB: the Pharmacogenomics Knowledge Base.

Authors:  Caroline F Thorn; Teri E Klein; Russ B Altman
Journal:  Methods Mol Biol       Date:  2013

Review 5.  Impact of the 1000 genomes project on the next wave of pharmacogenomic discovery.

Authors:  Wei Zhang; M Eileen Dolan
Journal:  Pharmacogenomics       Date:  2010-02       Impact factor: 2.533

6.  Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the "Missing Heritability" Problem.

Authors:  Kathrin Klein; Ulrich M Zanger
Journal:  Front Genet       Date:  2013-02-25       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.